MARCIA AUGUSTA DA SILVA

MARCIA AUGUSTA DA SILVA

Página do item completo

Resultados de Busca

Agora exibindo 1 - 6 de 6

Cytotoxic and genotoxic effects of I-131 and Co-60 in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment
2017 - VALGODE, FLAVIA G.S.; SILVA, MARCIA A. da; VIEIRA, DANIEL P.; RIBELA, MARIA T.C.P.; BARTOLINI, PAOLO; OKAZAKI, KAYO
Normally, differentiated thyroid cancer (DTC) tends to be biologically indolent, highly curable and has an excellent prognosis. However, the treatment may fail when the cancer has lost radioiodine avidity. The present study was carried out in order to evaluate the cytotoxic and genotoxic effects of I-131 and Co-60 and radioiodine uptake in WRO cells, derived from DTC, harboring the BRAF(V600E) mutation. WRO cells showed a relatively slow cell cycle of 96.3 h with an unstable karyotype containing various double minutes. The genotoxicity assay (micronucleus test) showed a relative high radioresistance to I-131 (0.07-3.70 MBq/mL), independent of treatment with recombinant human thyroid-stimulating hormone (rhTSH). For the cytotoxicity assay, WRO cells were also relatively resistant to Co-60 (range: 0.2-8.3 Gy), but with a gradual decrease of viability as a function of time for higher doses (20 and 40 Gy, starting from the fifth to sixth day). For internal irradiation with I-131, WRO cells showed a decline in viability at radioactive concentration higher than 1.85 MBq/mL; this was even more effective at 3.70 MBq/mL, but only when preceded by rhTSH, in coincidence with the highest level of I-131 uptake. These data show promising results, since the loss of the ability of thyroid cells to concentrate radioiodine is considered to be one of the main factors responsible for the failure of I-131 therapy in patients with DTC. The use of tumor-derived cell lines as a model for in vivo tumor requires, however, further investigations and deep evaluation of the corresponding in vivo effects.
Cytotogenic and dosimetric effects of sup(131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments
2016 - SILVA, MARCIA A. da; VALGODE, FLAVIA G.S.; GONZALEZ, JULIA A.; YORIYAZ, HELIO; GUIMARAES, MARIA I.C.C.; RIBELA, MARIA T.C.P.; BUCHPIGUEL, CARLOS A.; BARTOLINI, PAOLO; OKAZAKI, KAYO
A study directed to the cytogenetic and dosimetric aspects of radionuclides of medical interest is very valuable, both for an accurate evaluation of the dose received by the patients, and consequently of the genetic damage, and for the optimization of therapeutic strategies. Cytogenetic and dosimetric effects of 131I in lymphocytes of thyroidectomized differentiated thyroid cancer (DTC) patients were evaluated through chromosome aberration (CA) technique: Euthyroid patients submitted to recombinant human thyroid-stimulating hormone (rhTSH) therapy (group A) were compared with hypothyroid patients left without levothyroxine treatment (group B). CA analysis was carried out prior to and 24 h, 1 week, 1 month and 1 year after radioiodine administration (4995–7030 MBq) in both groups. An activity–response curve of 131I (0.074–0.740 MBq/mL) was elaborated, comparing dicentric chromosomes in vivo and in vitro in order to estimate the absorbed dose through Monte Carlo simulations. In general, radioiodine therapy induced a higher total CA rate in hypothyroid patients as compared to euthyroid patients. The frequencies of dicentrics obtained in DTC patients 24 h after treatment were equivalent to those induced in vitro (0.2903 ± 0.1005 MBq/mL in group A and 0.2391 ± 0.1019 MBq/mL in group B), corresponding to absorbed doses of 0.65 ± 0.23 Gy and 0.53 ± 0.23 Gy, respectively. The effect on lymphocytes of internal radiation induced by 131I therapy is minimal when based on the frequencies of CA 1 year after the treatment, maintaining a higher quality of life for DTC patients receiving rhTSHaided therapy.
Comparison of the cytogenetic effects of sup(131)I in patients with differentiated thyroid cancer with and without prior treatment with rhtsh
2013 - VALGODE, FLAVIA G.S.; SILVA, MARCIA A. da; GONZALEZ, JULIA A.; YORIYAZ, HELIO; GUIMARAES, MARIA I.C.C.; RIBELA, MARIA T. de C.P.; BUCHPIGUEL, CARLOS A.; BARTOLINI, PAOLO; OKAZAKI, KAYO
Induction of chromosomal aberrations in human lymphocytes by fission neutrons
2009 - SILVA, MARCIA A.; COELHO, PAULO R.P.; BARTOLINI, PAOLO; OKAZAKI, KAYO
Genotoxic evaluation of [DOTA, Tyrsup(3)]octreotate labelled with sup(131)I and sup(177)Lu in human peripheral lymphocytes in vitro by micronucleus assay
2007 - SUZUKI, MIRIAM F.; SILVA, MARCIA A. da; CALDEIRA FILHO, JOSE de S.; COLTURATO, MARIA T.; ARAUJO, ELAINE B. de; BARTOLINI, PAOLO; OKAZAKI, KAYO
[DOTA, Tyr3 ]octreotate has been used for cancer diagnosis and therapy because of its high affinity to somatostatin subtype receptors sstr2 and sstr5. The aim of this study was to evaluate the cytogenetic effect of radio-labelled [DOTA, Tyr3 ]octreotate in blood cells in vitro, using the cytokinesis-block micronucleus assay. Blood samples of healthy donors were exposed to different activities of [DOTA, Tyr3 ]octreotate labelled with 131I (n = 3) and 177Lu (n = 3), where radioactive concentration ranged from 600 to 5600 kBq/mL. The cells were cultivated according to criteria adopted by the IAEA (Vienna). The results showed a positive correlation between radioactive concentrations (X) and the frequency of binucleated cells with micronuclei (Y) (P < 0.05). The linear equations were similar: for the 131I labelled, Y = (1.634 ± 0.236) + (0.912 ± 0.137) 10–3 X and for the 177Lu labelled, Y = (1.715 ± 0.342) + (0.743 ± 0.135) 10–3 X.
Evaluation of the cytogenetic effects of 131I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats
2008 - SILVA, MARCIA A. da; GUIMARAES, MARIA I.C.C.; YORIYAZ, HELIO; RIBELA, MARIA T.C.P.; BUCHPIGUEL, CARLOS A.; BARTOLINI, PAOLO; OKAZAKI, KAYO
The present study was carried out to investigate the cytogenetic effects of therapeutic exposure to radioiodine preceded by rhTSH in an animal model. Three groups of Wistar rats (n = 6) were used: one group was treated only with 131I (11.1 MBq/animal); the other two groups received rhTSH (1.2 μg/rat of either Thyrogen or rhTSH-IPEN, respectively) 24 h before administration of radioiodine. The percentage of lymphocytes with chromosome aberrations and the average number of aberrations and of dicentrics per cell were determined on blood samples collected 24 h, 7 and 30 days after administration of 131I. The data show that the treatment with radioiodine alone or associated with rhTSH resulted in a greater quantity of chromosome alterations in relation to basal values after 24 h, with a gradual decline after 7 and 30 days of treatment. An increase in chromosome alterations was also seen after rhTSH treatment alone. Neither of the treatments, i.e., with 131I alone or associated with hormone, resulted in an aneugenic effect or influenced the kinetics of cellular proliferation in rat blood lymphocytes. There was no significant difference between the cytogenetic effects of Thyrogen and rhTSH-IPEN treatment. These data suggest that the treatment with radioiodine, associated or not with rhTSH, affects to a limited extent a relatively small number of cells although the occurrence of late stochastic effects could not be discarded.